药物超敏反应综合征发病及预后的相关进展  

Advances in the pathogenesis and prognosis of drug-induced hypersensitivity syndrome

作　　者：曹嘉力[1] 邢昕竹 范洁 何焱玲[1] CAO Jiali;XING Xinzhu;FAN Jie;He Yanling(Department of Dermatology,Beijing ChaoYang Hospital,Capital Medical University,Beijing 100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院皮肤科,北京100020 [2]北京市顺义区妇幼保健院医务科

出　　处：《实用皮肤病学杂志》2024年第2期93-96,106,共5页Journal of Practical Dermatology

摘　　要：药物超敏反应综合征(DIHS)又称为伴嗜酸粒细胞增多和系统症状的药疹,是一种特殊类型的重症药疹。临床表现以皮损、发热、淋巴结增大、血液学异常及多脏器受损为主,同时可伴有人疱疹病毒6(HHV-6)的重新激活。目前认为DIHS的发病机制是疱疹病毒和机体免疫反应之间复杂相互作用的结果,并与个体基因易感性等因素有关,趋化因子在发病过程中也起到重要作用。兹对DIHS发病机制及临床治疗、预后的相关进展进行综述。TDrug-induced hypersensitivity syndrome(DIHS),which is also called drug eruption with eosinophilia and systemic symptoms(DRESS),is one of the most severe adverse drug reactions.DIHS clinically presents as an extensive cutaneous rash with fever and lymphadenopathy,hematologic abnormalities and multiple organ involvement.In addition,It's usually accompanied with the re-activation of human herpesvirus-6(HHV-6)virus.Pathogenesis of DIHS has been linked to HHV-6 reactivation and immune reaction,and also related to genetic susceptibility.Chemokines play an important role in the progress.This review summarizes the progres in pathogenesis and prognosis of DIHS.

关 键 词：药物超敏反应综合征 基因 趋化因子 治疗 预后 

分 类 号：R758.25[医药卫生—皮肤病学与性病学]